Browse WNT2

Summary
SymbolWNT2
Namewingless-type MMTV integration site family member 2
Aliases IRP; secreted growth factor; INT1L1; Int-1-related protein; int-1-like protein 1; Protein Wnt-2
Chromosomal Location7q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix Secreted
Domain PF00110 wnt family
Function

Ligand for members of the frizzled family of seven transmembrane receptors. Functions in the canonical Wnt signaling pathway that results in activation of transcription factors of the TCF/LEF family (PubMed:20018874). Functions as upstream regulator of FGF10 expression. Plays an important role in embryonic lung development. May contribute to embryonic brain development by regulating the proliferation of dopaminergic precursors and neurons (By similarity).

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001654 eye development
GO:0001701 in utero embryonic development
GO:0001759 organ induction
GO:0001763 morphogenesis of a branching structure
GO:0001837 epithelial to mesenchymal transition
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0002053 positive regulation of mesenchymal cell proliferation
GO:0002088 lens development in camera-type eye
GO:0003002 regionalization
GO:0003007 heart morphogenesis
GO:0003156 regulation of animal organ formation
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003209 cardiac atrium morphogenesis
GO:0003228 atrial cardiac muscle tissue development
GO:0003230 cardiac atrium development
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0009952 anterior/posterior pattern specification
GO:0010092 specification of animal organ identity
GO:0010463 mesenchymal cell proliferation
GO:0010464 regulation of mesenchymal cell proliferation
GO:0010720 positive regulation of cell development
GO:0014706 striated muscle tissue development
GO:0014855 striated muscle cell proliferation
GO:0016055 Wnt signaling pathway
GO:0016202 regulation of striated muscle tissue development
GO:0016331 morphogenesis of embryonic epithelium
GO:0021953 central nervous system neuron differentiation
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030879 mammary gland development
GO:0030901 midbrain development
GO:0031128 developmental induction
GO:0032526 response to retinoic acid
GO:0033002 muscle cell proliferation
GO:0033278 cell proliferation in midbrain
GO:0035239 tube morphogenesis
GO:0035265 organ growth
GO:0040019 positive regulation of embryonic development
GO:0043010 camera-type eye development
GO:0045165 cell fate commitment
GO:0045844 positive regulation of striated muscle tissue development
GO:0045927 positive regulation of growth
GO:0045995 regulation of embryonic development
GO:0046620 regulation of organ growth
GO:0046622 positive regulation of organ growth
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048568 embryonic organ development
GO:0048592 eye morphogenesis
GO:0048593 camera-type eye morphogenesis
GO:0048608 reproductive structure development
GO:0048634 regulation of muscle organ development
GO:0048636 positive regulation of muscle organ development
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048644 muscle organ morphogenesis
GO:0048645 animal organ formation
GO:0048732 gland development
GO:0048738 cardiac muscle tissue development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048762 mesenchymal cell differentiation
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050769 positive regulation of neurogenesis
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051962 positive regulation of nervous system development
GO:0055008 cardiac muscle tissue morphogenesis
GO:0055009 atrial cardiac muscle tissue morphogenesis
GO:0055017 cardiac muscle tissue growth
GO:0055021 regulation of cardiac muscle tissue growth
GO:0055023 positive regulation of cardiac muscle tissue growth
GO:0055024 regulation of cardiac muscle tissue development
GO:0055025 positive regulation of cardiac muscle tissue development
GO:0060038 cardiac muscle cell proliferation
GO:0060043 regulation of cardiac muscle cell proliferation
GO:0060045 positive regulation of cardiac muscle cell proliferation
GO:0060070 canonical Wnt signaling pathway
GO:0060317 cardiac epithelial to mesenchymal transition
GO:0060415 muscle tissue morphogenesis
GO:0060419 heart growth
GO:0060420 regulation of heart growth
GO:0060421 positive regulation of heart growth
GO:0060423 foregut regionalization
GO:0060424 lung field specification
GO:0060425 lung morphogenesis
GO:0060428 lung epithelium development
GO:0060431 primary lung bud formation
GO:0060441 epithelial tube branching involved in lung morphogenesis
GO:0060485 mesenchyme development
GO:0060492 lung induction
GO:0060501 positive regulation of epithelial cell proliferation involved in lung morphogenesis
GO:0060502 epithelial cell proliferation involved in lung morphogenesis
GO:0060537 muscle tissue development
GO:0060541 respiratory system development
GO:0060562 epithelial tube morphogenesis
GO:0060571 morphogenesis of an epithelial fold
GO:0060572 morphogenesis of an epithelial bud
GO:0060674 placenta blood vessel development
GO:0060688 regulation of morphogenesis of a branching structure
GO:0060711 labyrinthine layer development
GO:0060716 labyrinthine layer blood vessel development
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061046 regulation of branching involved in lung morphogenesis
GO:0061047 positive regulation of branching involved in lung morphogenesis
GO:0061072 iris morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061180 mammary gland epithelium development
GO:0061351 neural precursor cell proliferation
GO:0061458 reproductive system development
GO:0071229 cellular response to acid chemical
GO:0071300 cellular response to retinoic acid
GO:0071396 cellular response to lipid
GO:0071542 dopaminergic neuron differentiation
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0090596 sensory organ morphogenesis
GO:0198738 cell-cell signaling by wnt
GO:1901861 regulation of muscle tissue development
GO:1901863 positive regulation of muscle tissue development
GO:1904948 midbrain dopaminergic neuron differentiation
GO:1904953 Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation
GO:1904954 canonical Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation
GO:1905330 regulation of morphogenesis of an epithelium
GO:1905332 positive regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
GO:2000794 regulation of epithelial cell proliferation involved in lung morphogenesis
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005109 frizzled binding
GO:0005125 cytokine activity
GO:0030545 receptor regulator activity
GO:0030546 receptor activator activity
GO:0048018 receptor agonist activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:1990909 Wnt signalosome
> KEGG and Reactome Pathway
 
KEGG hsa04150 mTOR signaling pathway
hsa04310 Wnt signaling pathway
hsa04390 Hippo signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04916 Melanogenesis
Reactome R-HSA-373080: Class B/2 (Secretin family receptors)
R-HSA-500792: GPCR ligand binding
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-195721: Signaling by Wnt
R-HSA-3238698: WNT ligand biogenesis and trafficking
Summary
SymbolWNT2
Namewingless-type MMTV integration site family member 2
Aliases IRP; secreted growth factor; INT1L1; Int-1-related protein; int-1-like protein 1; Protein Wnt-2
Chromosomal Location7q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between WNT2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between WNT2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29581358colorectal carcinomaInhibit immunityOverexpression of WNT2 and CADM1, associated with carcinogenesis and metastasis, in cancer-associated stromal cells suggests that both cancer cells and stromal cells play important roles in the development and progression of colorectal cancer through the formation of a tumor microenvironment.
Summary
SymbolWNT2
Namewingless-type MMTV integration site family member 2
Aliases IRP; secreted growth factor; INT1L1; Int-1-related protein; int-1-like protein 1; Protein Wnt-2
Chromosomal Location7q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of WNT2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolWNT2
Namewingless-type MMTV integration site family member 2
Aliases IRP; secreted growth factor; INT1L1; Int-1-related protein; int-1-like protein 1; Protein Wnt-2
Chromosomal Location7q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of WNT2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.0190.0165
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4460.56
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.4190.00949
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.2070.0581
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.8850.14
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3570.808
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2370.805
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4530.736
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2230.877
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6640.47
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4680.211
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0840.772
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of WNT2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277305.5-5.50.572
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolWNT2
Namewingless-type MMTV integration site family member 2
Aliases IRP; secreted growth factor; INT1L1; Int-1-related protein; int-1-like protein 1; Protein Wnt-2
Chromosomal Location7q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WNT2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolWNT2
Namewingless-type MMTV integration site family member 2
Aliases IRP; secreted growth factor; INT1L1; Int-1-related protein; int-1-like protein 1; Protein Wnt-2
Chromosomal Location7q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WNT2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WNT2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolWNT2
Namewingless-type MMTV integration site family member 2
Aliases IRP; secreted growth factor; INT1L1; Int-1-related protein; int-1-like protein 1; Protein Wnt-2
Chromosomal Location7q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WNT2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolWNT2
Namewingless-type MMTV integration site family member 2
Aliases IRP; secreted growth factor; INT1L1; Int-1-related protein; int-1-like protein 1; Protein Wnt-2
Chromosomal Location7q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of WNT2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolWNT2
Namewingless-type MMTV integration site family member 2
Aliases IRP; secreted growth factor; INT1L1; Int-1-related protein; int-1-like protein 1; Protein Wnt-2
Chromosomal Location7q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between WNT2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolWNT2
Namewingless-type MMTV integration site family member 2
Aliases IRP; secreted growth factor; INT1L1; Int-1-related protein; int-1-like protein 1; Protein Wnt-2
Chromosomal Location7q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting WNT2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.